EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis

Sining Xie, Federica Galimberti, Elena Olmastroni, Alberico L Catapano, Manuela Casula

Nutrition, Metabolism and Cardiovascular Diseases · 2026-10 · 36 (10) · 104851

DOI: 10.1016/j.numecd.2026.104851 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026-10. Verfasst von Sining Xie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Dyslipidemias, Lipids, Hypolipidemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Although the safety profile of lipid-lowering therapies (LLTs) is known, there are no comprehensive comparative assessments. We aimed to compare the risk of muscle-related events, diabetes, liver dysfunction, and cognitive disorders among LLTs through a network meta-analysis. METHODS AND RESULTS: Databases were searched from inception to May 2025. Eligible studies included adult patients, using statins, ezetimibe, PCSK9 monoclonal antibodies (PCSK9mAbs), inclisiran, bempedoic acid, or their combinations as intervention, reporting the information about any of the selected adverse events, a total sample size of ≥200 subjects, and had ≥1 month of intervention. Pooled estimates were assessed by fixed effects model within a frequentist setting. Pooled relative risks (RR) and their 95% confidence interval were estimated. A total of 303,397 subjects from 153 RCTs were included. Bempedoic acid ranked the lowest risk of myalgia (vs PCSK9mAbs, RR 0.80 [0.69, 0.93]). PCSK9mAbs were associated with lower incidence of creatine kinase (CK) elevation, diabetes, and liver dysfunction comparing to statins (statins vs PCSK9mAbs, RR 1.44 [1.14, 1.81], RR 1.13 [1.05, 1.22], and RR 1.38 [1.17, 1.62], respectively). In terms of muscle-related events and cognitive disorders, no significant risk differences were found among treatments and their combinations. CONCLUSIONS: PCSK9mAbs appear to have a more favourable safety profile regarding the risk of CK elevation, diabetes, and liver dysfunction. Bempedoic acid seem to be a better choice for subjects with high risk of myalgia. This information can be valuable when selecting therapy for specific patient subgroups at higher risk of certain adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasLipidsHypolipidemic AgentsHumansRisk FactorsTreatment OutcomeRisk AssessmentBiomarkersDrug Therapy, CombinationFemaleMaleMiddle AgedAgedProprotein Convertase 9PCSK9 InhibitorsFatty AcidsDiabetes MellitusHydroxymethylglutaryl-CoA Reductase InhibitorsDicarboxylic AcidsAdultMuscular DiseasesChemical and Drug Induced Liver Injury

Stichwörter der Autor:innen

Adverse eventsLipid-lowering therapiesNetwork meta-analysisSafety

Substanzen

BiomarkersLipidsProprotein Convertase 9Hypolipidemic AgentsPCSK9 InhibitorsPCSK9 protein, human8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidFatty AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsDicarboxylic Acids

Autor:innen und Institutionen

  • Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
  • IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy.
  • Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy.
  • Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy. Electronic addre…

Förderung

  • Ministero della Salute

Zitieren

APA

Xie, S., Galimberti, F., Olmastroni, E., Catapano, A. L., & Casula, M. (2026). Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 36(10), 104851. https://doi.org/10.1016/j.numecd.2026.104851

Vancouver

Xie S, Galimberti F, Olmastroni E, Catapano AL, Casula M. Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases. 2026;36(10):104851. doi:10.1016/j.numecd.2026.104851

BibTeX
@article{Xie2026,
  author = {Xie, Sining and Galimberti, Federica and Olmastroni, Elena and Catapano, Alberico L and Casula, Manuela},
  title = {Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2026},
  volume = {36},
  number = {10},
  pages = {104851},
  doi = {10.1016/j.numecd.2026.104851}
}
Kostenlos starten →